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ABSTRACT
Inhibition of the p16INK4a/cyclin D/CDK4/6/RB pathway is an effective 
therapeutic strategy for the treatment of estrogen receptor positive (ER+) breast 
cancer. Although efficacious, current treatment regimens require a dosing holiday due 
to severe neutropenia potentially leading to an increased risk of infections, as well 
as tumor regrowth and emergence of drug resistance. Therefore, a next generation 
CDK4/6 inhibitor that can inhibit proliferation of CDK4/6-dependent tumors while 
minimizing neutropenia could reduce both the need for treatment holidays and the 
risk of inducing drug resistance.
Here, we describe the preclinical characterization and development of G1T38; 
a novel, potent, selective, and orally bioavailable CDK4/6 inhibitor. In vitro, G1T38 
decreased RB1 (RB) phosphorylation, caused a precise G1 arrest, and inhibited 
cell proliferation in a variety of CDK4/6-dependent tumorigenic cell lines including 
breast, melanoma, leukemia, and lymphoma cells. In vivo, G1T38 treatment led 
to equivalent or improved tumor efficacy compared to the first-in-class CDK4/6 
inhibitor, palbociclib, in an ER+ breast cancer xenograft model. Furthermore, G1T38 
accumulated in mouse xenograft tumors but not plasma, resulting in less inhibition 
of mouse myeloid progenitors than after palbociclib treatment. In larger mammals, 
this difference in pharmacokinetics allowed for 28 day continuous dosing of G1T38 in 
beagle dogs without producing severe neutropenia. These data demonstrate G1T38 
has unique pharmacokinetic and pharmacodynamic properties, which result in high 
efficacy against CDK4/6 dependent tumors while minimizing the undesirable on-target 
bone marrow activity, thus potentially allowing G1T38 to be used as a continuous, 
daily oral antineoplastic agent.
INTRODUCTION
In normal cells, the cyclin D/CDK4/6/p16INK4a/
RB pathway allows for the orderly control of cell cycle 
progression for cell growth and proliferation. While the 
cyclin D/CDK4/6/p16INK4a/RB pathway is frequently 
disrupted in cancer, the majority of human neoplasms 
maintain functional RB but have aberrations that increase 
the activity of CDK4/6, which hyper-phosphorylates RB 
and allows cell proliferation [1, 2]. As such, CDK4/6 
appears to be a key enzyme necessary for the proliferation 
of human cancers that have functional RB.
Cell cycle progression begins with the commitment to 
transition from the G1 phase to the S phase; this restriction 
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point is regulated through RB. In the absence of a growth 
signal, RB inhibits the activation of genes required for S 
phase transition [1, 2]. Growth signals activate CDK4/6, 
which phosphorylates and deactivates RB, thus activating 
S phase-specific genes that stimulate cell cycle progression 
from the G1 phase to the S phase [3]. Further, inhibiting 
CDK4/6 activity has the potential to be therapeutically 
beneficial in a wide variety of tumors with functional RB.
There are numerous ways in which cancers with 
functional RB enhance CDK4/6 activity allowing for 
deregulated proliferation. One of the most common 
events is the inactivation of p16INK4a, a tumor suppressor 
that inhibits CDK4/6 activity. Inactivation of p16INK4a may 
occur via mutations, deletion, or epigenetic silencing, 
which is observed in a significant portion of non-small 
cell lung cancer, melanoma, pancreatic cancer, and 
mesothelioma [4–8].
Moreover, a specific mutation of the CDK4 gene 
(CDKR24C) that confers resistance to p16 INK4a binding has 
been shown to play a causal role in rare cases of familial 
melanoma, suggesting that unchecked CDK4 activity is a 
key event in these cancers [9]. Translocation or amplification 
of D-type cyclin genes that lead to increased CDK4/6 activity 
are found in the majority of mantle cell lymphomas and in 
many cases of multiple myeloma [10, 11]. Amplification of 
cyclin D1 and overexpression of the protein have also been 
reported in approximately 50% of squamous cell esophageal 
cancers and in 20% to 30% of breast cancers [12–14]. 
Specifically, the profiling of a breast cancer cell line panel 
with palbociclib, a selective CDK4/6 inhibitor, demonstrated 
that CDK4/6 inhibitors are exquisitely effective at inhibiting 
the growth of ER+ cells [15].
Additionally, many of the receptor-mediated growth 
pathways that are activated in human cancers increase 
D-type-cyclin transcription and expression to drive 
cellular proliferation [16, 17]. Other activating aberrations 
of mitogen pathways such as V600E B-Raf in the mitogen 
activated protein kinase pathway and phosphatase and 
tensin homolog deletions in the phosphatidylinositol-
3,4,5-trisphosphate 3-phosphatase (PTEN) pathway also 
increase D-type-cyclins to achieve unchecked proliferation 
[18, 19]. Furthermore, the genes encoding CDK4 and 
CDK6 are amplified in a subset of human neoplasms. 
The CDK4 gene is amplified in 100% of liposarcomas, 
while CDK6 is frequently amplified in T-lymphoblastic 
lymphoma and acute lymphoblastic leukemia [20, 21].
Finally, there is increasing evidence the E2F-
induced cyclin/CDK hyperactivity in prostate cancer 
is an ideal target for CDK4/6 inhibition [22]. Androgen 
receptor dependent upregulation of D-type-cyclins 
leading to activation of the cyclin D1/CDK4/6 complex 
and proliferation in prostate cancer cells suggests that 
targeting this axis may be effective in castration resistant 
prostate cancer (CRPC). Utilizing CRPC models, G1T38 
was observed to have equivalent anti-tumor activity to the 
standard of care, docetaxel. [Stice JP, Wardell SE, Norris, 
JD et al., in press].
The abundance of mechanisms by which 
transformed cells can deregulate CDK4/6 activity 
suggests this enzyme is crucial for cancer pathogenesis 
and inhibiting CDK4/6 activity has the potential to be 
therapeutically beneficial.
In February 2015, the first selective CDK4/6 
inhibitor, palbociclib, was approved by the Food and Drug 
Administration (FDA) to be used in combination with 
letrozole as initial endocrine-based therapy for the treatment 
of postmenopausal women with ER+, human epidermal 
growth factor receptor 2 (HER2) negative advanced or 
metastatic breast cancer. In February 2016, palbociclib was 
approved in combination with fulvestrant for the treatment 
of women with ER+, HER2- advanced or metastatic breast 
cancer with disease progression following endocrine therapy. 
Although palbociclib is efficacious, daily treatment causes 
severe neutropenia, which necessitates a 21-day on/7-day 
off schedule to allow for recovery of neutrophil counts [23, 
24]. The palbociclib-induced neutropenia may lead to an 
increased risk of infections and the treatment holiday may 
lead to the potential for tumor regrowth and emergence of 
drug resistance. This CDK4/6 dependent on-target effect 
on HSPC proliferation has been described previously [25, 
26], whereby early hematopoietic progenitor cells in the 
presence of palbociclib are maintained in a G1 arrested state 
until released. Continuous exposure decreases myelogenesis 
leading to myelosuppression, which is reversible. Thus, it 
may be advantageous to develop a next generation CDK4/6 
inhibitor that can inhibit cell proliferation in CDK4/6-
dependent tumors while minimizing effects on the bone 
marrow, thereby reducing the need for treatment holidays 
and decreasing the risk of inducing drug resistance.
Here we describe the preclinical development 
of G1T38: a novel, oral, potent and selective inhibitor 
of CDK4/6 that inhibits RB phosphorylation in 
vitro and in vivo. G1T38 is shown to possess unique 
pharmacokinetic and pharmacodynamic properties, 
which may enable a continuous dosing regimen. By 
minimizing undesirable on-target myelosuppression, 
G1T38 may obviate the need for a treatment holiday. 
G1T38 has recently been tested in a phase 1a, healthy 
volunteer pharmacokinetics and safety study (G1T38-01, 
NCT02821624). We are currently evaluating G1T38 (in 
combination with Faslodex) in a Phase 1b/2a trial in ER+, 
HER2- breast cancer patients (G1T38-02, NCT02983071).
RESULTS
Identification of G1T38
We have previously reported on a novel kinase 
inhibitor scaffold and the discovery of trilaciclib (G1T28), 
an IV, short-acting, potent and selective inhibitor of CDK4/6 
currently in clinical development to preserve HSPC and 
immune system function during chemotherapy [27]. 
Further development of the tricyclic lactam scaffold has 
produced a number of oral, potent and selective CDK4/6 
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inhibitors with excellent drug like properties. G1T38, 
2'-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7', 
8'dihydro-6'Hspiro[cyclohexane1,9' pyrazino[1',2':1,5]
pyrrolo[2,3-d]pyrimidin]-6'-one di-hydrochloride (Figure 
1A), was selected as a candidate oral antineoplastic 
agent with ideal physicochemical and pharmacokinetic/
pharmacodynamic (PK/PD) properties. G1T38 is highly 
potent and selective for CDK4/cyclin D1 and CDK6/
cyclin D3 over CDK1, CDK2, CDK5 and CDK7 and their 
respective binding partners (Table 1).
To determine kinase selectivity beyond the cyclin-
CDK family, we completed a screen of 468 protein kinases 
(KINOMEscan, DiscoveRx) at 100 nmol/ L and 1 μmol/L, 
which represents profiling at 100 and 1000 times the 
biochemical IC50 of G1T38. Results in Figure 1B show 
a high degree of selectivity at 100 nmol/L at an s-score 
of 1 (Figure 1B, left) and an s-score of 10 (Figure 1B, 
right). Protein kinases with off-target activity showing 
inhibition greater than 90% at 100 nmol/L were followed 
up for Kd determination (Supplementary Table 1). Within 
the CDK family, G1T38 is least selective against CDK9/
cyclin T; ~30 fold between CDK4/cyclin D1 and CDK9/
cyclin T at the biochemical IC50. The phosphorylation of 
RNA polymerase II (RPB1) CTD (SER2) was measured 
via immunoblot to determine whether G1T38 has a 
biological inhibitory effect on CDK9/cyclin T function. 
Results show that there is no loss of RPB1 CTD (SER2) 
phosphorylation in the presence of G1T38 (Supplementary 
Figure 1). Other targets demonstrating low Kd IC50 values 
include ULK2, an inducer of autophagy and NEK10, 
which is associated with G2/M arrest in response to UV 
irradiation. The effect of G1T38 on NEK10 and ULK2 
is an area of interest being further assessed as part of the 
investigation of this molecule.
G1T38 produces a precise G1 arrest of the cell 
cycle and a subsequent decrease in proliferation 
of CDK4/6-dependent cell lines
Next, we assessed the ability of G1T38 to elicit a 
G1 arrest in normal and tumorigenic CDK4/6-dependent 
(HS68, WM2664, respectively) and -independent 
tumorigenic (A2058) cell lines. G1T38 produced a robust 
and sustained G1 arrest in CDK4/6 dependent cells with an 
EC50 of ~20 nmol/L (Figure 1C). In CDK4/6 independent 
cells, the compound had no effect on the percentage of 
S-phase cells (as shown by arrow in Supplementary Figure 
1). A dose dependent increase of cells in the G1 phase of 
the cell cycle was observed when CDK4/6 dependent 
WM2664 cells were treated with G1T38 for 24 hours 
(Figure 1C). This arrest was maintained through 300 
nM, more than 300x the biochemical IC50. Additionally, 
both CDK4/6-dependent cell lines (HS68 and WM2664) 
had similar reductions in the S-phase population with 
concomitant increases in G1 arrested cells without a sub2N 
fraction demonstrating that G1T38 was not cytotoxic at 
the concentrations tested (Supplementary Figure 2). The 
CDK4/6-independent cell line (A2058) was not affected 
by treatment with G1T38.
The CDK4/cyclin D1 and CDK6/cyclin D3 
complexes are essential for progression from the G1 to 
the S-phase of the cell cycle through phosphorylation 
of the tumor suppressor, RB. Once phosphorylated, RB 
dissociates from cell cycle-promoting transcription factors, 
allowing them to drive the G1 to S-phase transition [28]. 
Therefore, CDK4/6 inhibition of RB phosphorylation will 
arrest cells in G1. To assess the effect of G1T38 on RB 
phosphorylation, WM2664 cells were treated with varying 
doses of G1T38 for 24 hours. After treatment, cells were 
harvested and phosphorylation of RB at the Ser807/811 
sites was evaluated via immunoblotting. Phosphorylation 
of RB at Ser807/811 sites first requires binding of CDK4/6 
[3] in order to progress into S-phase [3]. WM2664 cells 
treated with 30-1000 nM of G1T38 for 24 hours exhibited 
a complete inhibition of RB phosphorylation compared 
to vehicle controls (Figure 1D). To determine the kinetics 
of CDK4/6 inhibition on RB phosphorylation, WM2664 
cells were treated with 300 nM G1T38 for 1, 4, 8, 16, 
and 24 hours. As shown in Figure 1E, treatment with 
G1T38 reduced RB phosphorylation within 1 hour post-
treatment and generated near complete inhibition of RB 
phosphorylation by 16 hours post-treatment. Taken together, 
these data demonstrate G1T38 potently and completely 
inhibits phosphorylation of RB within 24 hours of exposure.
To assess the capacity of G1T38 to inhibit 
proliferation of tumor cell lines, a broad panel of CDK4/6 
dependent and independent lines was evaluated using 
CellTiter Glo (Table 2). The wide range of tumor lines 
was chosen to determine if G1T38 could globally inhibit 
proliferation via CDK4/6. G1T38 produced a robust 
Table 1: In vitro biochemical activity of G1T38
CDK4/
Cyclin 
D1
CDK6/ 
Cyclin 
D3
CDK9/ 
Cyclin T
CDK5/  
p35
CDK5/  
p25
CDK2/ 
Cyclin A
CDK1/ 
Cyclin B1
CDK7/ 
Cyclin H/ 
Mat1
CDK2/ 
Cyclin E
Mean
(μM)
.001 .002 .028 0.832 1.2 1.5 2.4 2.4 3.6
Biochemical profiling of G1T38 in Nanosyn, Inc. (Santa Clara, CA) kinase screen for CDKs. The assays were completed using 
microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose response 
format in singlicate at Km for ATP. Results are displayed as micromolar concentrations for IC50 curves against putative target.
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inhibition of proliferation in a diverse array of tumor 
cell lines including breast, melanoma, leukemia and 
lymphoma with EC50 concentrations as low as 23 nM. 
Furthermore, G1T38-associated inhibition in CDK4/6-
independent cell lines was greater than 2.5 μM (>2500x 
IC50) demonstrating a functional retinoblastoma pathway 
is essential for G1T38 activity.
Pharmacokinetics/pharmacodynamics of G1T38 
in an ER+ breast cancer model
To evaluate the murine PK/PD relationship of 
G1T38, an ER+ MCF7 xenograft model was utilized. 
Compound concentrations were measured in plasma 
and tumors from tumor-bearing mice given a single oral 
dose of G1T38 (100 mg/kg). Based on exposure, G1T38 
concentrations were 17-fold higher in the tumor compared 
to plasma (Figure 2A). The tumor drug concentration was 
>100 fold that of plasma at 24 hours and ~65 ng/ml of 
drug remained in the tumor at 48 hours while no drug 
was detectable in the plasma at this time. To assess the 
effects of G1T38 on pRB, tumors were harvested and 
pRB was analyzed by immunoblotting. Phosphorylated 
RB decreased 30% and 98% relative to the control at 1 
hour and 24 hours post-treatment, respectively (Figure 
2B). The phosphorylation of RB began to rebound by 
Figure 1: Chemical structure, kinome specificity and biochemical properties of G1T38. (A) Structure, molecular formula, 
and formula weight of G1T38. (B) Kinome binding specificity of G1T38 was measured by site- directed competition-binding assays 
(S-Score= 1, left, S-Score= 10, right). Blue circle represents CDK4/cyclin D3 (C) WM2664 cells show a dose-dependent G1 arrest with 
corresponding percent decrease in the number of cells in S-phase. (D) WM2664 cells treated with G1T38 for 24 hours show a dose-
dependent decrease in RB phosphorylation with complete inhibition of RB phosphorylation at a 300 nM exposure. (E) G1T38 (300 nM) 
time-dependent inhibition of RB phosphorylation demonstrating complete inhibition 24 hours post treatment. Total RB was assessed as a 
comparator to relative effect on RB phosphorylation and α-tubulin was used as the loading control.
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36 hours post-treatment and was approximately 31% of 
control levels at 48 hours post-treatment. The time course 
of pRB inhibition closely paralleled drug concentrations 
in the tumor but not the plasma as inhibition of pRB was 
maintained in the tumor hours after G1T38 was cleared 
from the plasma. These data suggest oral G1T38 has 
sufficient mouse PK/PD for assessing efficacy in tumor 
models.
G1T38 inhibits breast cancer tumor growth 
in vivo
We have previously shown that palbociclib is 
efficacious in the mouse mammary tumor virus (MMTV) 
- Neu GEMM (Her2/Neu) model, a model that is similar 
to human HER2-positive (HER2+) luminal breast cancer 
[29]. To assess the antineoplastic effect of G1T38 in this 
model, mice were given 100 mg/kg of G1T38 in their 
diet for 28 days with tumor measurements at treatment 
initiation and every 3 to 4 days during treatment. As 
shown in Figure 3A, mice treated with G1T38 elicited 
38% tumor regression after 21 days of treatment while 
control animals had a 577% increase in tumor burden over 
the same treatment period, demonstrating that G1T38 is 
highly efficacious in this HER2+ breast cancer model.
Next, the ER+ MCF7 xenograft model was utilized 
to assess efficacy of G1T38 relative to the first-in-class 
CDK4/6 inhibitor, palbociclib. Mice were given once daily 
doses of G1T38, palbociclib, or vehicle by oral gavage at 
10, 50, or 100 mg/kg for 28 days. Tumors were measured 
every 3 to 4 days during treatment for up to 20 days post-
treatment. Compared to the vehicle-treated mice, daily 
Table 2: Growth inhibitory effects of G1T38 on CDK4/6-dependent and CDK4/6-independent cell lines
Cell Line Tumor Type RB Status G1T38 EC
50
 (nM)
MV4-11 B cell leukemia + 23
MCF7 ER+ breast cancer + 52
SupT1 Lymphoma + 57
ZR-75-1 ER+ breast cancer + 61
WM2664 Melanoma + 125
Tom1 Ph1+ leukemia + 232
BV173 Ph1+ leukemia + 296
Daudi Lymphoma + 784
A2058 Melanoma - 2691
H69 SCLC - 2915
NALM1 Leukemia - >10000
EC50 concentrations (nM) of G1T38 and RB status of tumorigenic cell lines.
Figure 2: Pharmacokinetics and pharmacodynamics of G1T38 in ER+ breast cancer. (A) G1T38 concentration in tumor 
and plasma of C57BL/6 mice after a single oral 100 mg/kg dose of G1T38 (n=3 per time point). (B) RB phosphorylation levels in MCF7 
tumors from mice treated with a single oral dose of vehicle or 100 mg/kg of G1T38. The western blot shown is a representation of one set 
of tumors from analyzed samples.
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treatment with 100 mg/kg of G1T38 or palbociclib showed 
tumor regression within 10 days in the MCF7 xenograft 
model (Figure 3B). After 27 days of treatment, tumor 
growth inhibition (TGI) was observed in the 10, 50, and 
100 mg/kg G1T38 cohorts (approximately 12%, 74%, and 
90% inhibition, respectively); these data demonstrate that 
G1T38 can substantially inhibit cell growth in CDK4/6-
dependent tumors in vivo. Daily oral palbociclib treatment 
caused an 18%, 66%, and 87% tumor growth inhibition in 
the 10, 50, and 100 mg/kg dosage cohorts, respectively. 
Interestingly, at 50 mg/kg, G1T38 was significantly more 
efficacious than palbociclib. Similar results were seen in 
the ER+ ZR-75-1 breast cancer xenograft model when 
comparing G1T38 and palbociclib at the 50 mg/kg dose 
(Supplementary Figure 3).
G1T38 increases efficacy when combined with 
multiple targeted therapies in ER+ breast cancer
Currently, palbociclib is the only approved 
CDK4/6 inhibitor and is indicated for ER+ breast cancer 
in combination with letrozole or fulvestrant. To evaluate 
the antitumor efficacy of G1T38 in combination with 
endocrine therapy, the ER+ breast MCF7 xenograft 
model was utilized. Mice were treated with 50 mg/
kg G1T38, 20 mg/kg tamoxifen, or 5 mg fulvestrant, 
alone, or combinations of G1T38 + tamoxifen or G1T38 
+ fulvestrant. After 28 days of treatment, G1T38 + 
tamoxifen or G1T38 + fulvestrant were significantly more 
effective than any single agent (G1T38, tamoxifen, or 
fulvestrant) alone (Figure 4A). Furthermore, the G1T38 
combination treatment with either agent resulted in a near 
complete, sustained tumor regression.
As the only approved selective estrogen receptor 
degrader (SERD), fulvestrant is administered monthly 
through intramuscular (IM) injection due to its poor oral 
bioavailability. For this reason, combination therapy 
with an orally bioavailable SERD is highly desirable. 
We assessed the combination of G1T38 with GW5638, 
a non-commercialized orally available SERD, in the 
MCF7 model. Here, mice were treated with G1T38 
at 25 or 50 mg/kg alone, GW5638 at 25 mg/kg alone 
or in combination with G1T38 (Figure 4B). As single 
agents, there was modest TGI in this model, however, 
the combination of G1T38 and GW5638 led to sustained 
tumor regression confirming that G1T38 in combination 
with an orally available SERD increased efficacy in 
ER+ breast cancer potentially obviating the need for IM-
administered fulvestrant.
G1T38 increases efficacy of PI3K inhibitors in 
ER+ breast cancer xenograft model
Targeting the PI3K/AKT axis has been shown 
to provide an anti-proliferative effect through the 
reduction of AKT phosphorylation in ER+ breast cancer 
[30]. Preclinical studies have shown that targeting both 
the CDK4/6 and the PI3K signaling pathways results 
in tumor regression and reversal of PI3K inhibitor 
resistance in a MCF7 xenograft model [31]. To assess 
the effect of combining G1T38 with a PI3K inhibitor, 
we utilized the MCF7 xenograft model. A commercially 
available inhibitor of PI3kα/δ, GDC0941, was used 
for this study. Here, mice were treated with G1T38 
at 25 or 50 mg/kg, alone, GDC0941 at 100 mg/kg 
alone, or in combination. Results show there is modest 
Figure 3: Single agent efficacy of G1T38 in breast cancer. (A) Mice received 100 mg/kg of G1T38 or vehicle in their diet for 28 
days. Food pellets were prepared with the expectation that 100 mg/kg of G1T38 would be orally ingested per day under the parameters that 
25 gm mice eat 3.2 gm per day; these parameters were based on previous experience. After 21 days, tumor progression was calculated using 
the formula: (21 day volume – initial volume)/ initial volume x 100. (B) G1T38 or palbociclib efficacy after 28 days of oral treatment (100 
mg/kg, 50 mg/kg, 10 mg/kg) in MCF7 xenograft model. Yellow bar represents duration of treatment. Statistics were completed using linear 
regression analysis of time during treatment (28 days). Error bars represent SEM. **p≤0.01.
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Figure 4: Combination treatments with G1T38 in ER+ breast cancer and NSCLC. G1T38 in combination with tamoxifen 
or fulvestrant (A), SERD (GW5638) (B), PI3K inhibitor (GDC0941) (C), for 28 days of treatment in ER+ breast cancer xenograft model 
(MCF7). (D) G1T38 single agent efficacy in NSCLC PDX model CTG-0159 after 28 days of daily 100 mg/kg oral treatment. (E, F) G1T38 
in combination with oral EGFR inhibitors, erlotinib or afatinib, for 18 days of treatment in EGFR mutant NSCLC xenograft model (H1975). 
Statistics were completed using linear regression analysis of time during treatment. Error bars represent SEM. Yellow bar represents 
duration of treatment. **p≤0.01, ***p≤0.001, ****p≤0.0001.
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TGI as single agents. However, the combination of 
G1T38 and GDC0941 leads to greater efficacy than any 
of the treatments alone (Figure 4C). These data support 
combination therapy with G1T38 and a PI3K inhibitor in 
ER+ breast cancer.
G1T38 is efficacious as a single agent and also 
increases efficacy in combination with epidermal 
growth factor receptor (EGFR) inhibitors in 
EGFR mutated non-small cell lung cancer 
(NSCLC)
Preclinical studies have shown CDK4/6 inhibition is 
highly effective at inhibiting the growth of KRAS mutant 
NSCLC tumors [32]. To evaluate the efficacy of G1T38 in 
NSCLC, PDX tumor-bearing mice (CTG-0159: stage III 
primary squamous cell carcinoma, EGFRWT) were treated 
once daily with oral G1T38 at 100 mg/kg for 28 days. 
Tumors were measured every 3-4 days up to 30 days post 
treatment. After 28 days of treatment, G1T38 treated mice 
exhibited 77% TGI with an overall 60% tumor growth 
delay demonstrating G1T38 alone is highly efficacious in 
this NSCLC tumor model (Figure 4D).
To evaluate the efficacy of G1T38 in combination with 
EGFR inhibitors, the H1975 xenograft model was utilized. 
H1975 is a human NSCLC that harbors the EGFRL585R/T709M 
mutations rendering resistance to erlotinib treatment [33]. 
As expected, there was no significant difference between 
Figure 5: Comparison of myeloid precursor proliferation following G1T38 and palbociclib treatment. (A) Plasma 
concentrations of G1T38 or palbociclib 24 hours post 7 days treatment. (B) 12 hours post 7 days of treatment, bone marrow was harvested 
and proliferation (EdU incorporation) was measured in myeloid progenitors (Mac1+ Gr1+). (C) G1T38 and palbociclib neutrophil counts 
after 28 days of treatment in C57BL/6 mice. (D) Neutrophil counts and tumor volume in mice after 28 days of palbociclib or G1T38 daily 
oral treatment as previously described was analyzed using Michaelis-Menten nonlinear regression analysis. Vertical dotted line indicates 
size of tumor at treatment initiation. Horizontal dotted line indicates level of severe neutropenia in animals (50% of control neutrophil 
counts). Open circle indicates level of neutrophils and size of tumor after 28 days of daily oral vehicle treatment. (E) Neutrophil counts in 
beagle dogs during and after 28 days of G1T38 daily oral treatment (n=10; 5 males, 5 females). Yellow bar represents duration of treatment. 
Error bars represent SEM. *p≤0.05, **p≤0.01, ***p≤0.001.
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vehicle or erlotinib (70 mg/kg daily) treated mice. G1T38 
treatment as a single agent caused dose dependent TGI after 
50 and 100 mg/kg daily oral dosing (33.3% and 60.7%, 
respectively) by 18 days of treatment. Unexpectedly, when 
100 mg/kg G1T38 was combined with 70 mg/kg erlotinib 
for 18 days, there was 80% TGI when compared to vehicle 
treated cohorts (Figure 4E) demonstrating that combination 
therapy has greater efficacy than single agent therapy. 
Interestingly, when G1T38, at any dose, was combined with 
a 70 mg/kg dose of erlotinib, the resistance to the erlotinib 
was reversed suggesting the addition of GIT38 reverses the 
EGFR inhibitor resistance.
Afatinib is an irreversible second generation pan-
ErbB inhibitor developed as a first-line treatment of 
patients with metastatic NSCLC whose tumors harbor 
EGFR mutations or deletions as well as in patients with 
metastatic disease that progressed after platinum-based 
chemotherapy [34]. In the H1975 xenograft model, tumors 
treated in combination with G1T38 (50 or 100 mg/ kg) and 
afatinib (20 mg/ kg) did not develop resistance during the 
18 days of treatment (Figure 4F). However, within 14 days 
of treatment, the afatinib, only, cohort began to regrow 
suggesting the addition of G1T38 to an afatinib regimen 
can increase the time to resistance of the EGFR inhibitor 
in NSCLC.
Rapid clearance of G1T38 from plasma versus 
palbociclib leads to reduced myelosuppression in 
murine bone marrow
To better understand the relationship of CDK4/6 
inhibition and neutropenia, C57BL/6 mice were treated for 
7 days with G1T38 or palbociclib at 10, 50, or 100 mg/kg. 
After 7 days of daily oral dosing, palbociclib concentrations 
in plasma 24 hours after the final dose were ~300 ng/ml 
(approximately 600 nM; Figure 5A). This is significantly 
higher than the concentration necessary to inhibit cellular 
proliferation in most RB-dependent cell lines tested (Table 
2). In contrast, G1T38 plasma concentrations at 24 hours 
after the last dose were 11 ng/ml (approximately 22 nM); 
well below the concentration necessary to maintain a G1 
arrest. This suggests that palbociclib-induced neutropenia 
may be due to accumulation of the drug resulting in 
persistent inhibition of CDK4/6 in the bone marrow, thus 
preventing the recovery of bone marrow proliferation prior 
to subsequent doses.
To evaluate whether higher palbociclib exposures 
account for a more sustained inhibitory effect on the 
hematopoietic system than G1T38, mice were treated 
with various doses of G1T38 or palbociclib for 7 days 
and proliferation of the myeloid progenitor lineage 
was measured 12 hours post-treatment via 5-ethynyl-
2’-deoxyuridine (EdU) incorporation, a time point 
where previous experiments demonstrate bone marrow 
proliferation nadirs after a single dose of either compound. 
G1T38-treated mice showed no differences in myeloid 
progenitor proliferation in any treatment cohort when 
compared to vehicle, while palbociclib treatment led to 
more than a 50% reduction in proliferation in both the 50 
and 100 mg/kg cohorts (Figure 5B). These data indicate 
that between doses, the longer exposure of palbociclib 
resulted in drug concentrations that were above the 
threshold necessary to maintain G1 arrest of bone 
marrow progenitor cells resulting in sustained inhibition 
of myeloid progenitors. In contrast, due to the minimal 
G1T38 compound in the plasma at 24 hours, the bone 
marrow seem to have more time to recover from CDK4/6 
inhibition between doses suggesting that continuous daily 
dosing may be achievable in cancer patients.
To compare the effects of G1T38 and palbociclib 
on neutrophils during daily treatment, neutrophils were 
measured at Days 0, 14, and 28. As shown in Figure 5C, 
a dose-dependent decrease in neutrophils was observed 
with maximal effect in the 100 mg/kg G1T38 cohort with 
a 48% decrease in neutrophils demonstrated after 28 days 
of once daily oral dosing. The decrease in neutrophils was 
similar in the palbociclib-treated cohorts (Figure 5C). 
Thus, it appears the difference between palbociclib and 
G1T38 inhibition of myeloid progenitors in murine bone 
marrow is not sufficient to further reduce the number of 
circulating neutrophils. Therefore, in mice, the therapeutic 
index (TI) (the difference between tumor efficacy and 
neutropenia) for dosing G1T38 and palbociclib appears 
similar. To confirm, an Emax model was generated to 
compare neutrophil counts to tumor efficacy in both 
G1T38 and palbociclib treated cohorts. As shown in 
Figure 5D, there is a close correlation between G1T38 and 
palbociclib suggesting that both drugs equally affect tumor 
proliferation and neutrophil counts, confirming there is no 
difference in the TI in mice.
However, in GLP 28-day toxicology studies in 
beagle dogs, neutrophils decreased rapidly in a dose 
dependent manner during the first 14 days of G1T38 
treatment. However, from 14 to 25 days, cells reached 
a steady state level, which was readily reversible once 
dosing was stopped (Figure 5E). While the decrease in 
neutrophil count was higher as the dose increased, the 
neutrophil count at each dose level did not decrease further 
once the nadir level was achieved at 14 days. These data 
suggest that continuous daily dosing, without a break, may 
be achievable in cancer patients.
DISCUSSION
The therapeutic importance of CDK4/6 as a target 
has been established by palbociclib (IBRANCE®), a first-
in-class CDK4/6 inhibitor, which is approved for the 
treatment of hormone receptor (HR)-positive and human 
epidermal receptor 2 (HER2)-negative breast cancer 
in combination with the aromatase inhibitor, letrozole, 
or the SERD, fulvestrant [35]. Although palbociclib 
has proven efficacious, daily treatment causes severe 
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neutropenia, which necessitates a 7-day treatment holiday 
[23, 24]. Palbociclib-induced neutropenia may lead to 
an increased risk of infections and the treatment holiday 
may lead to tumor outgrowth and emergence of drug 
resistance. Therefore, a next generation CDK4/6 inhibitor 
should inhibit CDK4/6-dependent tumor growth while 
minimizing neutropenia, thereby reducing the need for 
treatment holidays and decreasing the risk of inducing 
drug resistance.
Here, we have identified and characterized G1T38; 
a potent and highly selective CDK4/6 inhibitor with 
antiproliferative activity in CDK4/6- dependent cells and 
tumors. Biochemical profiling against the CDK family 
showed G1T38 was most potent on CDK4/ cyclin D1 
(1 nM), CDK6/ cyclin D3 (2 nM) and CDK9/ cyclin T 
(28 nM). G1T38 was >1000 fold selective for CDK4/ 
cyclin D1 than CDK2/cyclin E and CDK2/cyclin A. 
When profiled against a broader panel of kinases, G1T38 
was highly selective against the majority of kinases. We 
investigated whether G1T38 might be affecting pathways 
regulated through CDK9 inhibition, but did not see an 
effect on RNA polymerase II. Interestingly, G1T38 is 
highly potent against FLT3 (D835V) and FLT3 (ITD, 
D835V) while not against FLT3 wild type protein. While 
high levels of wild-type expression is observed in acute 
myelogenous leukemia and B-cell acute lymphoblastic 
leukemia, the mutant forms are manifested as leukemic 
driver mutations resulting in uncontrolled receptor 
activation and are associated with negative outcome [36]. 
We did not observe a FLT3 specific effect on myelogenesis 
with G1T38 outside the CDK4/6 inhibitory effect on 
bone marrow. In WM2664 cells, G1T38 produced a dose 
dependent G1 arrest with an EC50= 20 nM. This G1 arrest 
was maintained through at least 300 nM. The G1 arrest 
was concomitant with inhibition of pRB. However, in 
cells where the RB pathway was disrupted, G1T38 had 
no cell cycle effect through 2.5 μM demonstrating that 
the G1 arrest was specific for CDK4/6-dependent cells. 
Additionally, G1T38 was not toxic to the cells, as we 
observed no decrease in cell proliferation, morphological 
change or increase in sub 2N in cell populations where the 
RB pathway was disrupted.
G1T38 has a relatively short plasma half-life with 
minimal accumulation upon repeat dosing. In tumor bearing 
mice, we found that while G1T38 was readily cleared 
from the plasma, it appeared to accumulate in tumors. We 
found that the concentrations of G1T38 in tumors closely 
correlated with inhibition of tumor pRB, demonstrating that 
G1T38 in the tumor could inhibit the CDK4/6/RB pathway 
and sustain tumor cell growth inhibition after G1T38 plasma 
concentrations were <1 ng/ml. Assuming the bone marrow 
compartment has similar drug concentrations to circulating 
drug in the plasma, the differential drug concentrations in the 
bone marrow and tumor could allow for a larger TI. These 
unique PK/PD properties may allow for continuous daily 
dosing in the clinic
Previously, we reported palbociclib significantly 
inhibited HER2+ tumor growth in the MMTV-HER2-neu 
GEMM when orally dosed for 28 days [29]. Here, we 
found that G1T38 was highly efficacious in this model 
demonstrating that G1T38 and palbociclib are equally 
effective as single agents and confirming that HER2+ 
tumors are sensitive to CDK4/6 inhibition. Studies 
comparing G1T38 to palbociclib in a human ER+ mouse 
xenograft model demonstrate equivalent or better single 
agent efficacy (Figure 3B and Supplementary Figure 3). 
When comparing the plasma exposures of G1T38 and 
palbociclib to efficacy (% TGI) in a nonlinear regression 
model, G1T38 had a 3.8 fold lower EC50 than palbociclib 
(Supplementary Figure 4). This most likely reflects both 
the greater biochemical and cellular potency of G1T38 
(IC50=1 nM vs. IC50 =10 nM for palbociclib; G1T38 
EC50=2-3 fold < palbociclib) and difference in PK 
properties of the compounds.
Preclinical studies have generally shown that 
CDK4/6 inhibitors have greater efficacy when given in 
combination with various growth signaling inhibitors 
(GSI) [37]. Likewise, in clinical studies, combination 
therapies targeting CDK4/6 and ER signaling pathways 
have been shown to significantly increase progression free 
survival [38, 39]. Thus, further development of CDK4/6 
inhibitors will most likely be done in combination with 
GSIs. In multiple combination studies targeting CDK4/6, 
ER, and PI3K pathways in human ER+ mouse xenograft 
models, G1T38 was significantly more efficacious when 
combined with the GSI then as a single agent (Figure 
4). In most of these studies, tumors began proliferating 
within a few days once dosing was stopped. However, 
the combination of G1T38 with GW5638, fulvestrant or 
tamoxifen was particularly efficacious and TGI persisted 
for several weeks once dosing was stopped. Furthermore, 
the addition of G1T38 increased the efficacy of an anti-
estrogen treatment independent of G1T38 dose (Figure 
4B). These data suggest lower doses of CDK4/6 inhibitors 
and GSIs could be used in combination to decrease 
toxicity while remaining highly efficacious.
In NSCLC, combination studies targeting CDK4/6 
and EGFR signaling also showed increased efficacy when 
compared to single agent therapy. In fact, the combination 
of G1T38 (50 mg/kg) and erlotinib was equally efficacious 
as the G1T38 (100 mg/kg) alone cohort. Interestingly, 
G1T38 also reversed erlotinib-resistance. While it has 
been previously shown that JAK2 inhibition re-sensitizes 
NSCLC to EGFR inhibitors and G1T38 inhibits JAK2, 
the IC50 was >500 nm; a concentration that is too 
high for any biological relevance [40]. Additionally, 
upregulation of AXL leads to EGFR inhibitor resistance 
in NSCLC causing activation of MAPK, AKT and NFkB 
pathways [41]. CDK4/6 inhibition has been shown to 
affect signaling in all three pathways [42–44] suggesting 
a possible mechanism whereby G1T38 reverses the 
resistance of erlotinib in EGFR mutant NSCLC.
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As we have previously shown that bone marrow 
hematopoietic stem and progenitor cells are CDK4/6 
dependent [He S, Roberts PJ, Sorrentino JA, et al., in 
press]. Thus, the neutropenia observed in the clinic with 
CDK4/6 inhibitors is a consequence of the on-target effect 
of prolonged drug exposure, which has resulted in dosing 
regimens that require at least a 7-day treatment holiday to 
allow recovery of neutrophils. These studies also indicate 
a narrow TI between tumor efficacy and neutropenia. This 
is most likely due to the long half-life and accumulation of 
palbociclib with repeat dosing. Thus drug exposure may be 
prolonged above the threshold to maintain arrest of bone 
marrow myeloid progenitors, resulting in more severe 
neutropenia. In fact, palbociclib has a half-life of >24 hours 
in humans with a median accumulation ratio of 2.4 (range 
1.5-4.2) [35]. To better address the narrow TI, G1T38 was 
designed to have minimal accumulation on repeat dosing 
while maintaining tumor efficacy. In mice, the effects of 
G1T38 and palbociclib on neutrophils were similar and 
reflected the nearly identical elimination half-lives of these 
compounds. However, unlike G1T38, sustained plasma 
concentrations of palbociclib at 24 hours after administration 
caused a decrease in myeloid progenitors, i.e., a more 
sensitive target population than circulating neutrophils. 
The minor difference observed in mouse PK and myeloid 
progenitors appears to be exacerbated in larger mammals 
leading to longer half-lives, accumulation of drug, and 
increased sensitivity to CDK4/6 inhibition (Supplementary 
Table 2). The toxicity of palbociclib was only evaluated for 
21 days in repeat dose GLP toxicology studies in rat and 
dog, rather than the standard 28-day studies [45], whereas, 
G1T38 was assessed in 28-day repeat-dose GLP toxicity 
studies in rat and dog. With oral administration of G1T38, 
anticipated reduction of bone marrow cellularity and 
lymphocyte depletion was observed leading to dose-related 
decreases in hematopoiesis. However, at clinically relevant 
doses, these effects were not sufficient to limit dosing to 
less than 28 days. There were no reported increases in the 
incidence of infection or bleeding throughout dosing and 
inhibition of hematopoiesis was found to be reversible upon 
discontinuing dosing of G1T38 during the recovery period. 
Additionally, there was no accumulation of G1T38 as 
measured by PK on repeat dosing through 28 days in either 
rats or dogs (Supplementary Table 3). These data suggest 
G1T38 has the potential to be dosed continuously in humans 
at an efficacious level.
In summary, we have identified and characterized 
G1T38 as a novel, potent, selective and orally 
bioavailable small molecule inhibitor of CDK4/6 that 
shows significant efficacy in CDK4/6 dependent tumors 
by effectively inhibiting tumor growth without causing 
severe neutropenia. G1T38 may, therefore, be an optimal 
therapeutic for daily use as an oral antineoplastic agent, 
allowing for a greater TI than palbociclib. G1T38 has 
recently completed testing in human subjects in a Phase 
1 healthy volunteer study to assess safety, PK, and 
tolerability in 75 healthy subjects [46]. We are currently 
evaluating G1T38 (in combination with Faslodex) in a 
Phase 1b/2a trial in ER+, HER- breast cancer patients [47].
MATERIALS AND METHODS
Chemicals
G1T38: 2'-((5-(4-isopropylpiperazin-1-yl)pyridin-
2-yl)amino)-7',8'dihydro-6'H-spiro[cyclohexane1,9'p
yrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one di-
hydrochloride was synthesized and characterized for 
purity and identity as an HCl salt at ChemoGenics 
BioPharma, LLC under the direction of G1 Therapeutics, 
Inc. GW5638: was synthesized at PharmAdvance 
(Jiangyin, Jiangsu, P.R. China).
Nanosyn CDK biochemical in vitro assay
Compounds were tested in CDK1/CYCLIN B1, 
CDK2/CYCLIN A, CDK2/CYCLIN E, CDK4/CYCLIN 
D1, CDK6/CYCLIN D3, CDK5/p25, CDK5/p35, CDK7/
CYCLIN H-MAT1, and CDK9/CYCLIN T kinase assays 
(Nanosyn, Inc.; Santa Clara, CA). The assays were 
completed using microfluidic kinase detection technology 
(Caliper Assay Platform). The compounds were tested in 
12-point dose response format in singlicate at the Km for 
ATP. Phosphoacceptor substrate peptide concentration 
used was 1 μM and Staurosporine was used as the 
reference compound for all assays.
KINOMEscan primary screen and Kd 
determination
G1T38 was profiled at DiscoveRx (Fremont, CA) 
using their KINOMEscan and scanMAX screening 
technology [48]. Briefly, G1T38 was tested at 100 and 
1000 times the biochemical IC50 as described in Figure 
1B. All target kinases that responded to greater than 90% 
inhibition were tested as individuals for Kd determination 
as described in Supplementary Table 1.
Cell lines
Cell lines were obtained from American Type 
Culture Collection (ATCC; Manassas, VA) or Leibniz-
Institut DSMZ-Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH (Braunscheig, Germany). HS68 
(CRL-1635™) and A2058 (CRL-11147™) cells were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Life Technologies/ Thermo Fisher Scientific, (Waltham, 
MA) containing 10% fetal bovine serum (HyClone/ 
GE Healthcare; Pittsburgh, PA) and 1x Glutamax (Life 
Technologies). MCF-7 (HTB-22™) and WM2664 (CRL-
1676™) cells were grown in Eagle’s Modified Dulbecco’s 
Medium (EMEM) (Life Technologies) containing 10% 
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fetal bovine serum and 1x Glutamax. ZR-75-1 (CRL-
1500™), NCI-H69 (HTB-119™), Daudi (CCL-213™) 
and SUP-T1 (CRL-1942™) were grown in RPMI-1640 
(CELLGRO/ Corning; Corning, NY) containing 10% fetal 
bovine serum and 1x Glutamax. NALM-1 (CRL-1567™) 
cells were grown in RPMI-1640 (CELLGRO) containing 
15% fetal bovine serum and 1x Glutamax. MV-4-11 (CRL-
9591) cells were grown in Iscove’s Modified Dulbecco’s 
Medium (IMDM) (ATCC). BV173 (ACC-20) and Tom-1 
(ACC-578) cells were grown in RPMI-1640 (CELLGRO) 
containing 20% heat inactivated fetal bovine serum 
(Hyclone) and 1 x Glutamax. Heat inactivation of fetal 
bovine serum was performed by warming serum to 37°C 
with mixing, then placing the serum in 56°C water bath 
for 30 minutes with mixing every 15 minutes, followed 
by cooling immediately in ice bath. Serum was stored at 
-20°C until ready for use. Cell lines were authenticated by 
ATCC in September 2105 and Genetica DNA Laboratories 
(Burlington, NC) in October 2016 using short tandem 
repeat (STR) profiling.
Western blot analysis for pRb and total Rb
WM2664 cells were either treated for dose response 
(3, 10, 30, 100, 300 or 1000 nM) for 24 hours or a time course 
(1, 4, 8, 16 or 24 hours) with 300 nM G1T38. Whole cell 
extracts were prepared using 1x radioimmunoprecipitation 
assay buffer (RIPA) (ThermoFisher) containing 1x HALT® 
protease and phosphatase inhibitors (ThermoFisher). 
Total protein concentration was determined by using the 
bicinchoninic acid (BCA) Protein Assay Kit (PIERCE/ 
ThermoFisher), according to manufacturer’s instructions. 
20 micrograms of protein were heat denatured for 10 
minutes at 70°C and resolved by Novex® NuPAGE® 
SDS-PAGE gel system (ThermoFisher) at 200 volts, 
constant current and transferred to 0.45 μm nitrocellulose 
membrane (Life Technologies) in 1 x Transfer buffer (Life 
Technologies) plus 20% methanol (Sigma-Aldrich (St. 
Louis, MO) by electroblotting at 35 volts, constant current. 
Membranes were blocked in LiCor Membrane Blocking 
Buffer (Lincoln, NE) and incubated overnight with either 
rabbit anti-pRb (Ser807/811, CST-9308) antibody (Cell 
Signaling Technology (Danvers, MA) at a 1:500 dilution or 
mouse anti-Rb (CST-9309) at a 1:2,000 dilution and mouse 
α-tubulin (CST-3873) antibody (Cell Signaling Technology) 
at a 1:1,000 dilution, as a loading control. Secondary 
antibodies (LiCor) were goat anti- rabbit (680RD) and goat 
anti-mouse (800CW) at a 1:15,000 dilution. Blots were 
incubated for one hour, washed and imaged using LiCor 
ImageStudio software (Version 4.0.21).
Cell proliferation
SupT1, Daudi, MCF7, ZR-75-1, A2058, WM2664, 
and H69 cells were seeded at 1000 cells per well; MV-4-11 
and BV173 cells were plated at 4000 cells per well; Tom-
1 cells were plated at 8,000 cells per well; NALM-1 cells 
were plated at 20,000 cells per well in Costar 3903 96 well 
plates. After 24 hours, plates were dosed with G1T38 at a 
nine-point dose concentration from 10 μM to 1 nM. Cell 
viability was determined after four or six days using the 
CellTiter-Glo® assay (Promega; Madison, WI) following 
manufacturer’s recommendations. Plates were processed 
on BioTek (Winooski, VT) Synergy2 multi-mode plate 
reader and data analyzed using GraphPad (San Diego, CA) 
Prism 5 statistical software.
Ethics statement
In vivo investigation has been conducted in 
accordance with the ethical standards and according to the 
Declaration of Helsinki and according to the international 
guidelines and has been approved by each contract 
research organization’s institutional review board.
MCF-7 breast cancer xenograft model
South Texas Accelerated Research Therapeutics 
(START; San Antonio, Texas) evaluated the antitumor 
activity of G1T38 in a START Cell-Based Xenograft 
(START-CBX) tumor model, MCF-7, representing 
human breast cancer. Data collected from this efficacy 
study included animal weights, observations, and tumor 
dimensions. This information was used to determine agent 
tolerability based on weight change and gross physiologic 
changes, and anticancer activity based on tumor growth 
inhibition or regression. Study endpoint was Day 60. 
MCF-7 cells were harvested from culture and injected 
into immune-deficient mice and the study initiated at a 
mean tumor volume of approximately 150-250 mm3. In 
all studies, G1T38 and palbociclib was given as a daily 
oral treatment at 10, 25, 50 or 100 mg/kg. Tamoxifen 
was administered subcutaneous (s.c.) at 20 mg/kg M-F, 
fulvestrant was administered s.c. 5 mg per mouse once 
a week, GW5638 was administered orally at 25 mg/kg 
daily and GDC0941 (Selleckchem) was administered 
orally at 100 mg/kg daily for the duration of each study. 
Tumor growth inhibition (%TGI) was calculated using 
the following equation: %TGI=(1-(((TV
tmtfinal
-TVtmtinitial))/
((AVERAGE(TV
ctlfinal
))-(AVERAGE(TVctlinital)))))*100. All 
protocols were IACUC approved and experiments were 
completed at START.
Her2Neu breast cancer GEMM
Female MMTV-NEU mice (Jackson Labs Strain 
002376) were used to test the efficacy of G1T38 (100 
mpk, medicated diet). Drug was incorporated into diet by 
Research Diets (New Brunswick, NJ) using the following 
parameters; 25 gm mouse eating 3.2 gm of food/day. Mice 
were monitored for tumor development by palpating them 
weekly as per University of North Carolina at Chapel 
Hill Lineberger Mouse Phase 1 Unit (MP1U) protocol. 
At time of treatment, body composition was assessed 
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and weight measurements (in grams) were recorded and 
used as a measure of gross toxicity. Mice were monitored 
until euthanized at predetermined humane endpoints per 
approved University of North Carolina at Chapel Hill 
IACUC protocols.
CTG0159 PDX NSCLC model
Female nude mice were implanted with NSCLC 
PDX CTG0159 tumor. Mice were then randomized into 
treatment groups and dosing initiated once tumors reached 
a volume that fell within the range of 150-300 mm3. 100 
mg/kg G1T38 or vehicle was orally administered for 28 
consecutive days. Tumors were measured twice weekly 
until mice reached tumor burden of 1500 mm3. All 
protocols were IACUC approved and experiments were 
completed at Champions Oncology (Baltimore, MD).
H1975 NSCLC xenograft model
Female NCI Ath/nu mice were implanted with 
H1975 NSC lung adenocarcinoma model. Once tumors 
reached an average size of 100- 150 mm3, mice were 
randomized into treatment cohorts. Mice were orally 
administered daily afatinib (20 mg/kg, Genentech/OSI), 
erlotinib (70 mg/kg, LC Labs), or G1T38 (50 or 100 
mg/kg), as single agents or in combination (G1T38 + 
erlotinib or G1T38 + afatinib) for the duration of the study. 
Tumors were measured twice weekly until mice reached 
tumor burden of 1500 mm3. All protocols were IACUC 
approved and experiments were completed at Charles 
River Laboratories (CRL; Research Triangle Park, NC).
In vivo G1T38 murine pharmacokinetic (PK) 
assay
For PK analysis comparing G1T38 levels in tumor 
and plasma, MCF7 tumor bearing mice were given a 
single oral gavage at 100 mg/kg of G1T38 and blood 
via cardiac puncture and tumors were harvested at 0 
(predose), 6, 12, 24, 36, 48 hours post treatment. For 
7-day continuous oral PK analysis, C57BL/6 mice were 
administered daily oral gavages of 10, 50 or 100 mg/kg 
of G1T38 or palbociclib for 7 consecutive days. Blood 
was collected from treated mice via cardiac puncture 24 
hours post drug administration (3 mice/dose/time-point). 
Plasma G1T38 concentration was determined by LC-
MS/MS following standard protocols. PK analyses on 
plasma G1T38 concentration were performed in Watson 
(v7.3.0.01, Thermo Inc., Philadelphia, PA).
Inhibition of Rb phosphorylation in MCF-7 
tumors
Mice carrying MCF-7 xenograft tumors were 
orally dosed once with vehicle or G1T38 at 100 mg/kg. 
Tumors were harvested at 1, 6, 24, 36, or 48 hours, rinsed 
in phosphate buffered saline -calcium magnesium free 
(PBS-CMF) and snap frozen in liquid nitrogen. Tumors 
were then lysed in RIPA buffer containing protease and 
phosphatase inhibitors on ice and homogenized using 
Biomasher II mini-pestle (Kimble Chase Life Sciences, 
Vineland, NJ) until fully dissociated. Protein concentration 
determination and western blot analysis methods for pRB 
Ser 807/811 as previously described.
Peripheral blood analysis of G1T38 and 
palbociclib in mice
C57BL/6 female mice were given daily oral doses 
of vehicle, palbociclib or G1T38 at 10, 50 or 100 mg/kg 
for 28 days. CBCs were measured every two days starting 
on day six. Data reported are from day 6 (Platelets), 
day 10 (white blood cells [WBC], neutrophils [Neu], 
lymphocytes[Lymph]), or day 16 (red blood cells [RBC]). 
All protocols were IACUC approved and experiments 
were completed at Integrated Laboratory Systems 
(Research Triangle Park, NC).
CBC and PK analysis in G1T38 treated beagle 
dogs
Beagle dogs (5/ sex) were dosed once daily for 28 
consecutive days via oral gavage. The dose levels were 1, 
2.5 and 5 mg/kg/day and administered at a dose volume 
of 5 mL/kg. Hematology samples (1ml/ time point) were 
collected in K3EDTA tubes twice pre-test and then on days 
7, 14, 21, and 25 during the dosing period and on days 35, 
and 42 during the recovery period. Complete blood counts 
were performed and results reported. All studies were 
conducted utilizing methods and protocols in accordance 
with IACUC approval at MPI Research (Mattawan, MI).
EdU incorporation in G1T38 and palbociclib 
treated mice
C57BL/6 mice were administered daily oral 
gavages of 10, 50 or 100 mg/kg of G1T38 or palbociclib 
for 7 consecutive days. Eleven hours later, each mouse 
was given a single IP injection of 10 mg/kg EdU and 
femurs harvested 1 hours later (3 mice/dose/time-point). 
All protocols were IACUC approved and experiments 
were completed at Integrated Laboratory Systems. Bone 
marrow cells were isolated by flushing the femurs using 
ice-cold staining medium (1× Ca2+- and Mg2+-free Hank's 
balanced salt solution (HBSS, Gibco) supplemented 
with 10 mM EDTA (Corning) and 2% heat-inactivated 
bovine serum (Gibco)) and filtered through 40-μm nylon 
mesh (ThermoFisher). The cells were then fixed in 5% 
formalin for 10 minutes on ice and permeabilized in 
staining medium plus 0.1% saponin for 10 minutes at 
room temperature. EdU staining was completed using 
manufactures’ instructions (Life Technologies). Flow 
cytometry analysis of stained cells was completed on a 
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LSR II 3-laser flow cytometer (Becton-Dickinson), and 
recorded data was analyzed in FlowJo 10.0.8 software.
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